We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The AstraZeneca and Daiichi Sankyo HER2-targeting drug/antibody conjugate garnered headlines at the European Society for medical Oncology meeting last week, posting wins in metastatic HER2+ breast cancer, advanced gastric cancer, and non-small cell lung cancer. Read More
BeyondSpring Pharmaceuticals’ lung cancer drug plinabulin showed statistically significant improvement in overall survival in its phase 3 trial conducted in China. Read More
Pfizer-BioNTech’s COVID-19 vaccine for kids age five to 11 years appears ready for prime time as the first results from the companies’ trial of a COVID-19 vaccine in this age group are released. Read More
The data showed that the booster vaccination, administered to adults two years after the initial vaccination, induced a strong immune response within seven days. Read More
Amgen reported that adding its Vectibix (panitumumab) antibody to a cell proliferation blocker more than doubled response rates compared to the blocker alone in patients withKRAS G12C-mutated advanced colorectal cancer (CRC). Read More
AbCellera and Moderna have teamed up in a multi-year effort to leverage AbCellera’s artificial intelligence-powered technology to identify therapeutic antibodies against up to six targets chosen by Moderna. Read More
Johnson & Johnson (J&J) has reported that its Ebola vaccine generated antibody immune responses in adults and children that lasted for two years. Read More
A fourth boy has died in Astellas Gene Therapies’ 24-patient ASPIRO study of AT132, an adeno-associated virus vector treatment for myotubular myopathy. Read More